Mologic and Alamar team up to fight future threats from Covid

Mologic in Bedford UK and Maine in the US and Alamar Biosciences in California are partnering on the project.

The collaboration will utilise Alamar’s novel antibodies against SARS-CoV-2 Nucleocapsid (N) protein for Mologic’s future COVID-19 RDTs.

Easy-to-use and cost-effective RDTs are a key tool for controlling the spread of COVID-19, including in low resource settings. Mologic has already launched COVID-19 antigen tests (COVIOS and COVIGO for personal self-testing) based on its lateral flow assay technology, utilising high affinity, paired antibodies specific for the SARS-CoV-2 nucleoprotein antigen.  Read more

Related Posts

University of Maine recruiting homeowners for tick surveys

ORONO, Maine — With tick season upon us, researchers at the University of Maine want to know what Mainers are doing...

25 April 2023

Maine’s oldest bioscience symposium turns 50 on MDI

Students and accomplished science leaders share research on Mt. Desert Island This April 20 marked the 50th anniversary meeting of the...

23 April 2023

Husson University students, faculty share projects at 13th annual Research Showcase

BANGOR, Maine — Today marked Husson University’s 13th annual Research and Scholarship Day. Students and faculty members at Husson shared the...

20 April 2023